Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. 10 stocks we like better than ...

REC-3565, a MALT1 inhibitor developed via AI, is now in Phase 1 for blood cancers. REC-617 showed encouraging signs in a patient with recurrent ovarian cancer. Get the data-driven signals to profit ...

What if we told you that some Boeing planes can lift their nose without anyone touching the yoke — oh, and this can happen while the plane is parked at the gate? It's a very real phenomenon called ...

As part of the “Treasure Tail: Zoshigaya” quest in Persona 5: The Phantom X, you’ll need to help the Orange Tabby Cat find their Orange Tabby Treasures around Zoshigaya. After you interact with the ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Before we jump in, we'd like to define what exactly a "classic" car is — and in truth, there's no one answer. That said, American Collectors Insurance describes a classic car as being between "20 and ...